Drugs / MET642
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04773964 | Mar 2021 → Dec 2022 | metabolic dysfunction-associated steatohepatitis | Metacrine, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET642 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04773964 ↗ |